Outcome of therapy-related myeloid neoplasms treated with azacitidine

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Fianchi, Luana ^a   Criscuolo, Marianna ^a   Lunghi, Monia ^b   Gaidano, Gianluca ^b   Breccia, Massimo ^c   Levis, Alessandro ^d   Finelli, Carlo ^e   Santini, Valeria ^f   Musto, Pellegrino ^g   Oliva, Esther N ^h   Leoni, Pietro ⁱ   Spiriti, Antonietta Aloe ^j   Dal, Francesco ^a   Hohaus, Stefan ^a   Pagano, Livio ^a   Leone, Giuseppe ^a   Voso, Maria Teresa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Ospedale di Alessandria   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Ematologia Firenze   (Italy)

^g REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^h BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁱ Ematologia Ancona   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

Hypomethylating agents; Therapy related myeloid neoplasms

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; KARYOTYPE; LYMPHOBLAST; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIMARY TUMOR; REMISSION; RETROSPECTIVE STUDY; SEPSIS; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84864400766     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-44     Document Type: Article

References (30)

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. JW Vardiman, J Thiele, DA Arber, RD Brunning, MJ Borowitz, A Porwit, NL Harris, MM Le Beau, E Hellström-Lindberg, A Tefferi, CD Bloomfield, Blood 2008 114 937 951
2. Therapy-related myeloid neoplasms. G Leone, L Fianchi, MT Voso, Curr Opin Oncol 2011 23 672 680 10.1097/CCO.0b013e32834bcc2a 21918440
3. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. N Mauritzson, M Albin, L Rylander, R Billström, T Ahlgren, Z Mikoczy, J Björk, U Strömberg, PG Nilsson, F Mitelman, L Hagmar, B Johansson, Leukemia 2002 16 2366 2378 10.1038/sj.leu.2402713 12454741 (Pubitemid 36067289)
4. Genetic pathways leading to therapy-related myeloid neoplasms. A Stoddart, ME McNerney, E Bartom, R Bergerson, DJ Young, Z Qian, J Wang, AA Fernald, EM Davis, RA Larson, KP White, MM Le Beau, Mediterr J Hematol Infect Dis. 2011 3 2011019 21713073
5. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. S Kayser, K Döhner, J Krauter, CH Köhne, HA Horst, G Held, M von Lilienfeld-Toal, S Wilhelm, A Kündgen, K Götze, M Rummel, D Nachbaur, B Schlegelberger, G Göhring, D Späth, C Morlok, M Zucknick, A Ganser, H Döhner, RF Schlenk, Blood 2011 117 2137 2145 10.1182/blood-2010-08-301713 21127174
6. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. DH Christiansen, MK Andersen, J Pedersen-Bjergaard, Leukemia 2003 17 1813 1819 10.1038/sj.leu.2403054 12970781 (Pubitemid 37185257)
7. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. M Greco, F D'Al A Scardocci, M Criscuolo, E Fabiani, F Guidi, A Di Ruscio, G Migliara, L Pagano, L Fianchi, P Chiusolo, S Hohaus, G Leone, MT Voso, Blood Cells Mol Dis 2010 45 181 185 10.1016/j.bcmd.2010.05.008 20655775
8. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. A Scardocci, F Guidi, F D'Alo', D Gumiero, E Fabiani, A Di Ruscio, M Martini, LM Larocca, M Zollino, S Hohaus, G Leone, MT Voso, Br J Cancer 2006 95 1108 1113 10.1038/sj.bjc.6603392 17047656 (Pubitemid 44606840)
9. Epigenetic changes in therapy-related MDS/AML. MT Voso, F D'Al M Greco, E Fabiani, M Criscuolo, G Migliara, L Pagano, L Fianchi, F Guidi, S Hohaus, G Leone, Chem Biol Interact 2010 84 46 49
10. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. SM Smith, MM Le Beau, D Huo, T Karrison, RM Sobecks, J Anastasi, JW Vardiman, JD Rowley, RA Larson, Blood 2003 102 43 52 10.1182/blood-2002-11-3343 12623843 (Pubitemid 36759634)
11. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. C Chang, BE Storer, BL Scott, EM Bryant, HM Shulman, ME Flowers, BM Sandmaier, RP Witherspoon, RA Nash, JE Sanders, A Bedalov, JA Hansen, BE Clurman, R Storb, FR Appelbaum, HJ Deeg, Blood 2007 110 1379 1387 10.1182/blood-2007-02-076307 17488876 (Pubitemid 47281440)
12. Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. RA Larson, MM Le Beau, Mediterr J Hematol Infect Dis. 2011 3 2011032 21869918
13. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. D Grimwade, H Walker, G Harrison, F Oliver, S Chatters, CJ Harrison, K Wheatley, AK Burnett, AH Goldstone, Blood 2001 98 1312 1320 10.1182/blood.V98.5.1312 11520776
14. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, A Giagounidis, R Schoch, N Gattermann, G Sanz, A List, SD Gore, JF Seymour, JM Bennett, J Byrd, J Backstrom, L Zimmerman, D McKenzie, C Beach, LR Silverman, Lancet Oncol 2009 10 223 232 10.1016/S1470-2045(09)70003-8 19230772
15. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. R Itzykson, S Thépot, B Quesnel, F Dreyfus, O Beyne-Rauzy, P Turlure, N Vey, C Recher, C Dartigeas, L Legros, J Delaunay, C Salanoubat, S Visanica, A Stamatoullas, F Isnard, A Marfaing-Koka, S de Botton, Y Chelghoum, AL Taksin, I Plantier, S Ame, S Boehrer, C Gardin, CL Beach, L Adès, P Fenaux, Blood 2011 117 403 411 10.1182/blood-2010-06-289280 20940414
16. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with azacitidine. K Raj, A John, A Ho, C Chronis, S Khan, J Samuel, S Pomplun, NS Thomas, GJ Mufti, Leukemia 2007 21 1937 1944 10.1038/sj.leu.2404796 17611569 (Pubitemid 47299967)
17. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. BD Cheson, JM Bennett, KJ Kopecky, T Büchner, CL Willman, EH Estey, CA Schiffer, H Doehner, MS Tallman, TA Lister, F Lo-Coco, R Willemze, A Biondi, W Hiddemann, RA Larson, B Löwenberg, MA Sanz, DR Head, R Ohno, CD Bloomfield, J Clin Oncol 2003 21 4642 4649 10.1200/JCO.2003.04.036 14673054 (Pubitemid 46594039)
18. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. BD Cheson, PL Greenberg, JM Bennett, B Lowenberg, PW Wijermans, SD Nimer, A Pinto, M Beran, TM de Witte, RM Stone, M Mittelman, GF Sanz, SD Gore, CA Schiffer, H Kantarjian, Blood 2006 108 419 425 10.1182/blood-2005-10-4149 16609072 (Pubitemid 44061337)
19. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. ML Sorror, MB Maris, R Storb, F Baron, BM Sandmaier, DG Maloney, B Storer, Blood 2005 106 2912 2919 10.1182/blood-2005-05-2004 15994282 (Pubitemid 41510773)
20. Similarities and differences between therapy-related and elderly acute myeloid leukemia. F D'Al L Fianchi, E Fabiani, M Criscuolo, M Greco, F Guidi, L Pagano, G Leone, MT Voso, Mediterr J Hematol Infect Dis 2011 3 2011052 22220249
21. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, N Gattermann, U Germing, G Sanz, AF List, S Gore, JF Seymour, H Dombret, J Backstrom, L Zimmerman, D McKenzie, CL Beach, LR Silverman, J Clin Oncol 2010 28 562 569 10.1200/JCO.2009.23.8329 20026804
22. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. L Malcovati, MG Della Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, F Passamonti, L Arcaini, M Maffioli, P Bernasconi, M Lazzarino, M Cazzola, J Clin Oncol 2005 23 7594 7603 10.1200/JCO.2005.01.7038 16186598 (Pubitemid 46291823)
23. The WHO Classification of MDS does make a difference. RB Howe, A Porwit-MacDonald, R Wanat, R Tehranchi, E Hellström-Lindberg, Blood 2004 103 3265 3270 10.1182/blood-2003-06-2124 14684416 (Pubitemid 38525649)
24. Prognosis in therapy related acute myeloid leukemia and impact of karyotype. W Kern, T Haferlach, S Schnittger, W Hiddemann, C Schoch, J Clin Oncol 2004 22 2510 2511 10.1200/JCO.2004.99.301 15197216 (Pubitemid 41115412)
25. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). S Murphy, Thromb Haemost 1997 78 622 626 9198227 (Pubitemid 27289315)
26. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. BI Carr, S Rahbar, Y Asmeron, A Riggs, CD Winberg, Br J Cancer 1988 857 395 402
27. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. A Stathis, SJ Hotte, EX Chen, HW Hirte, HW Hirte, AM Oza, P Moretto, S Webster, A Laughlin, LA Stayner, S McGill, L Wang, WJ Zhang, I Espinoza-Delgado, JL Holleran, MJ Egorin, LL Siu, Clin Cancer Res 2011 17 1582 1590 10.1158/1078-0432.CCR-10-1893 21278245
28. Epigenetics in cancer: what's the future? Y Boumber, JP Issa, Oncology 2011 25 220 226 228 21548464
29. Response to azacitidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. F D'Al G Leone, S Hohaus, L Teofili, V Bozzoli, MC Tisi, V Rufini, ML Calcagni, MT Voso, Br J Haematol 2011 154 141 143 10.1111/j.1365-2141.2010.08438.x 21332703
30. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. L Fianchi, L Pagano, F Leoni, S Storti, MT Voso, CG Valentini, S Rutella, A Scardocci, M Caira, G Gianfaldoni, G Leone, Ann Oncol 2008 19 128 134 17906298